The closing price of Novo Nordisk ADR (NYSE: NVO) was $128.05 for the day, down -1.05% from the previous closing price of $129.41. In other words, the price has decreased by -$1.36 from its previous closing price. On the day, 3934053 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of NVO’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 96.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 35.93. For the most recent quarter (mrq), Quick Ratio is recorded 0.64 and its Current Ratio is at 0.82. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on January 23, 2024, initiated with a Overweight rating and assigned the stock a target price of $120.
On December 01, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $120.Cantor Fitzgerald initiated its Overweight rating on December 01, 2023, with a $120 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVO now has a Market Capitalization of 570.99B and an Enterprise Value of 570.52B. As of this moment, Novo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 47.40, and their Forward P/E ratio for the next fiscal year is 31.13. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 16.93. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.86 while its Price-to-Book (P/B) ratio in mrq is 27.44. Its current Enterprise Value per Revenue stands at 2.46 whereas that against EBITDA is 4.98.
Stock Price History:
Over the past 52 weeks, NVO has reached a high of $138.28, while it has fallen to a 52-week low of $75.56. The 50-Day Moving Average of the stock is 121.43, while the 200-Day Moving Average is calculated to be 100.14.
Shares Statistics:
NVO traded an average of 5.13M shares per day over the past three months and 4.12M shares per day over the past ten days. A total of 3.38B shares are outstanding, with a floating share count of 3.38B. Insiders hold about 0.00% of the company’s shares, while institutions hold 9.15% stake in the company. Shares short for NVO as of Feb 29, 2024 were 4.67M with a Short Ratio of 0.80, compared to 7.52M on Jan 31, 2024.
Dividends & Splits
With its trailing 12-month dividend rate of 9.40, NVO has a forward annual dividend rate of 1.81. Against a Trailing Annual Dividend Yield of 7.26%, it implies a Forward Annual Dividend Yield of 1.07%. The stock’s 5-year Average Dividend Yield is 1.65. The current Payout Ratio is 36.04% for NVO, which recently paid a dividend on Apr 02, 2024 with an ex-dividend date of Mar 22, 2024. Stock splits for the company last occurred on Jan 09, 2014 when the company split stock in a 5:1 ratio.
Earnings Estimates
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of $0.75 for the current quarter, with a high estimate of $0.79 and a low estimate of $0.68, while EPS last year was $0.64. The consensus estimate for the next quarter is $0.77, with high estimates of $0.84 and low estimates of $0.72.
Analysts are recommending an EPS of between $3.59 and $3.2 for the fiscal current year, implying an average EPS of $3.36. EPS for the following year is $3.97, with 7 analysts recommending between $4.51 and $3.58.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $9.6B to a low estimate of $9.07B. As of the current estimate, Novo Nordisk ADR’s year-ago sales were $7.59B, an estimated increase of 23.90% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $9.85B, an increase of 23.60% less than the figure of $23.90% in the same quarter last year. There is a high estimate of $10.38B for the next quarter, whereas the lowest estimate is $9.38B.
A total of 6 analysts have provided revenue estimates for NVO’s current fiscal year. The highest revenue estimate was $44.06B, while the lowest revenue estimate was $40.02B, resulting in an average revenue estimate of $41.69B. In the same quarter a year ago, actual revenue was $33.76B, up 23.50% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $49.27B in the next fiscal year. The high estimate is $53.48B and the low estimate is $44.59B. The average revenue growth estimate for next year is up 18.20% from the average revenue estimate for this year.
